Evidence map›Paper›PMID 26468205›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2015

Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.

Alexandra Alvarsson, Xiaoqun Zhang, Tiberiu L Stan, Nicoletta Schintu, Banafsheh Kadkhodaei, Mark J Millan, Thomas Perlmann, Per Svenningsson

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Preclinical development of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  8. Article
  9. Article
  10. TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HTNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Article
  11. Article
  12. Trace amine-associated receptor 1 and drug abuse.Advances in pharmacology (San Diego, Calif.) · 2022
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Alexandra AlvarssonDepartment of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, SE-17176 Stockholm, Sweden, alexandra.alvarsson@ki.se per.svenningsson@ki.se.
Xiaoqun ZhangDepartment of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, SE-17176 Stockholm, Sweden.
Tiberiu L StanDepartment of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, SE-17176 Stockholm, Sweden.
Nicoletta SchintuDepartment of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, SE-17176 Stockholm, Sweden.
Banafsheh KadkhodaeiLudwig Institute for Cancer Research, SE-17177 Stockholm, Sweden.
Mark J MillanPole of Innovation in Neuropsychiatry, Institut de Recherches Servier, Centre de Recherches de Croissy, Paris 87290, France, and.
Thomas PerlmannLudwig Institute for Cancer Research, SE-17177 Stockholm, Sweden, Department of Cell and Molecular Biology, Karolinska Institutet, SE-17177 Stockholm, Sweden.
Per SvenningssonDepartment of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, SE-17176 Stockholm, Sweden, alexandra.alvarsson@ki.se per.svenningsson@ki.se.
Karolinska Institutet · SELudwig Cancer Research · SEPlateforme Technologique d'Innovation Biomédicale · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a movement disorder characterized by a progressive loss of nigrostriatal dopaminergic neurons. Restoration of dopamine transmission by l-DOPA relieves symptoms of PD but causes dyskinesia. Trace Amine-Associated Receptor 1 (TAAR1) modulates dopaminergic transmission, but its role in experimental Parkinsonism and l-DOPA responses has been neglected. Here, we report that TAAR1 knock-out (KO) mice show a reduced loss of dopaminergic markers in response to intrastriatal 6-OHDA administration compared with wild-type (WT) littermates. In contrast, the TAAR1 agonist RO5166017 aggravated degeneration induced by intrastriatal 6-OHDA in WT mice. Subchronic l-DOPA treatment of TAAR1 KO mice unilaterally lesioned with 6-OHDA in the medial forebrain bundle resulted in more pronounced rotational behavior and dyskinesia than in their WT counterparts. The enhanced behavioral sensitization to l-DOPA in TAAR1 KO mice was paralleled by increased phosphorylation of striatal GluA1 subunits of AMPA receptors. Conversely, RO5166017 counteracted both l-DOPA-induced rotation and dyskinesia as well as AMPA receptor phosphorylation. Underpinning a role for TAAR1 receptors in modulating glutamate neurotransmission, intrastriatal application of RO5166017 prevented the increase of evoked corticostriatal glutamate release provoked by dopamine deficiency after 6-OHDA-lesions or conditional KO of Nurr1. Finally, inhibition of corticostriatal glutamate release by TAAR1 showed mechanistic similarities to that effected by activation of dopamine D2 receptors. These data unveil a role for TAAR1 in modulating the degeneration of dopaminergic neurons, the behavioral response to l-DOPA, and presynaptic and postsynaptic glutamate neurotransmission in the striatum, supporting their relevance to the pathophysiology and, potentially, management of PD. SIGNIFICANCE STATEMENT: Parkinson's disease (PD) is characterized by a progressive loss of nigrostriatal dopaminergic neurons. Restoration of dopamine transmission by l-DOPA relieves symptoms of PD but causes severe side effects. Trace Amine-Associated Receptor 1 (TAAR1) modulates dopaminergic transmission, but its role in PD and l-DOPA responses has been neglected. Here, we report that TAAR1 potentiates the degeneration of dopaminergic neurons and attenuates the behavioral response to l-DOPA and presynaptic and postsynaptic glutamate neurotransmission in the striatum, supporting the relevance of TAAR1 to the pathophysiology and, potentially, management of PD.

Indexed as

Adrenergic AgentsAkathisia, Drug-InducedAnimalsAntiparkinson AgentsCocaineCorpus StriatumDisease Models, AnimalDopamineDopamine and cAMP-Regulated Phosphoprotein 32Dopamine Plasma Membrane Transport ProteinsGlutamic AcidLevodopaMaleMiceMice, Inbred C57BLMice, Knockout2beta-carbomethoxy-3beta-(4-iodophenyl)tropaneAdrenergic AgentsAntiparkinson AgentsCocaineDopamineDopamine and cAMP-Regulated Phosphoprotein 32Dopamine Plasma Membrane Transport ProteinsGlutamic AcidLevodopaOligodeoxyribonucleotides, AntisenseOxidopamineRadiopharmaceuticalsReceptors, G-Protein-CoupledTrace Amine-Associated ReceptorsTyrosine 3-Monooxygenasedyskinesial-DOPAParkinsonismTAAR1trace amine

Identifiers

PMID26468205
PMCPMC6608178
OpenAlexW2274979321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.